Navigation Links
Dyadic International To Present At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech
Date:5/29/2013

JUPITER, Fla., May 29, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), announced today that its President and CEO, Mark Emalfarb , will present at the World Biotechnology Congress 2013 in Boston, Massachusetts and the BIO World Congress on Industrial Biotech in Montreal, Canada.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic is a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Emalfarb's presentation at the World Biotechnology Congress will take place on June 6th, from 11:20 – 11:40 a.m. EDT, in Lecture Hall No. 201 (Level 2) at the John B. Hynes Veterans Memorial Convention Center.

Titled "Dyadic's C1 Enzyme Technology Update: On the Road to Cellulosic Sugars for Fuels and Chemicals," Emalfarb will discuss Dyadic's license agreements, commercial developments and progress toward producing cost-competitive cellulosic biofuels from agricultural byproducts such as corn stover and wheat straw.

Emalfarb will also co-chair the Industrial and Manufacturing session scheduled for Thursday, June 6th, from 2:00 – 5:10 p.m. EDT in Lecture Hall No. 201.  The session will feature presentations on next-generation biofuels and new routes toward the development of novel antifungal therapeutics, among others.

At the BIO World Congress on Industrial Biotech on June 18th, Emalfarb will participate on a panel called "Global Benefits for Synthetic Biology Tools" from 10:30 a.m. – 12:00 p.m. EDT at the Palais des Congres de Montreal.

"Dyadic is making significant progress towards producing economically viable cellulosic biofuels and chemicals from C1-derived enzymes," said Emalfarb.  "For instance, we expect that our C1 platform will be used to produce enzymes in commercial volumes when Abengoa Energy starts up its commercial scale cellulosic ethanol biorefinery in Hugoton, Kansas later this year."

Emalfarb continued, "We look forward to providing an update on this and other commercial developments at both of these internationally recognized scientific conferences."

About World Biotechnology Congress 2013

The World Biotechnology Congress 2013 will focus on various important disciplines of biotechnology and its applications for improvement in health and quality of life the world over.  It is anticipated that up to 1000 of the world's leading scientists, researchers, industrialists and academicians, including several Nobel Laureates, in the fields of biotechnology as well as medical and biological sciences, will attend this forum in Boston, to share and discuss new scientific ideas, products and breakthroughs.

About BIO World Congress

The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event for business leaders, investors, and policy makers in biofuels, bio-based products, and renewable chemicals.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Reports First Quarter 2013 Financial Results
2. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
3. Danai Brooks Joins Dyadic International as Chief Operating Officer
4. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
5. Dyadic International To Present At World Biofuels Markets
6. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
7. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
8. 12th U.S. Patent Issued To Dyadic International
9. Dyadic International Reports 2012 Third Quarter Financial Results
10. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
11. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... Delpor, Inc. (Delpor), ... grant from the National Institute of Mental Health (NIMH) for the further advancement of ... PROZOR technology and is expected to deliver therapeutic levels of olanzapine for ...
(Date:2/24/2017)... FRANCISCO , Feb. 24, 2017 Symic ... is developing a new category of therapeutics, announced today ... of SB-030 in peripheral artery disease. The trial will ... administered single-use therapeutic, in the reduction of restenosis following ... this critical development milestone for SB-030," said Nathan ...
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):